|
News For AMRN;VVUS From The Last 14 Days Check below for free stories on AMRN;VVUS the last two weeks. |
|
|
| May 17, 2013 |
| 14:12 EDT |  | AMRN | Amarin shares slip after FDA updates Orange Book
 Subscribe for More Information |
|
| May 15, 2013 |
| 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. |
|
| May 14, 2013 |
| 10:01 EDT |  | VVUS | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. |
|
| 07:33 EDT | | VVUS | VIVUS downgraded to Neutral from Buy at Lazard Capital
Subscribe for More Information |
|
| May 13, 2013 |
| 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information |
|
| 07:41 EDT | | VVUS | VIVUS mails letter to stockholders providing business update
Subscribe for More Information |
|
| May 10, 2013 |
| 09:23 EDT |  | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. |
|
| May 9, 2013 |
| 16:18 EDT |  | AMRN | Amarin reports Q1 EPS (41c), consensus (39c)
Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. |
|
| 13:15 EDT | | AMRN | Amarin, Omthera drop following fatty acids study in journal
Subscribe for More Information |
|
| May 8, 2013 |
| 07:35 EDT | | VVUS | VIVUS reports Q1 EPS (53c), consensus (51c)
Reports Q1 revenue $4.11M, consensus $5.22M. |
| |
| May 7, 2013 |
| 16:52 EDT | | VVUS | First Manhattan Co. releases case for full board change at VIVUS
Subscribe for More Information |
|
|
|
|
|
